Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Migraine Disorders
Interventions
NP101 - Sumatriptan iontophoretic transdermal patch, Placebo
Drug
Lead sponsor
NuPathe Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
530 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
34
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Newport Beach, California + 31 more
Conditions
Back Pain
Interventions
Buprenorphine transdermal patch, Placebo oxycodone/acetaminophen tablets, OXY/APAP, Placebo transdermal patch (TDS)
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 1998
U.S. locations
12
States / cities
Huntsville, Alabama • Phoenix, Arizona • Gainesville, Florida + 7 more
Conditions
Cigarette Smoking, Drug Use
Interventions
Standard Treatment, BAD-AS, Transdermal Nicotine Patch
Behavioral · Drug
Lead sponsor
University of Maryland, College Park
Other
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Conditions
Contraception
Interventions
Gestodene/EE Patch (BAY86-5016)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 45 Years · Female only
Enrollment
1,502 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
63
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 54 more
Conditions
Nausea and Vomiting, Ovarian Brenner Tumor, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Stage II Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIA Ovarian Cancer, Stage IIB Fallopian Tube Cancer, Stage IIB Ovarian Cancer, Stage IIC Fallopian Tube Cancer, Stage IIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Undifferentiated Ovarian Carcinoma
Interventions
Adjuvant Therapy, Aprepitant, Carboplatin, Cisplatin, Dexamethasone, Granisetron Transdermal Patch, Management of Therapy Complications, Questionnaire Administration
Procedure · Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
2
States / cities
Hinsdale, Illinois • Providence, Rhode Island
Completed Not applicable Interventional Accepts healthy volunteers

Nicotine Patch, Blood Flow and Oxidative Stress Study

NCT00954096
Conditions
Healthy
Interventions
transdermal nicotine patch (7mg)
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002 – 2006
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Behavioral Activation Therapy and Nicotine Replacement Therapy in Increasing Smoking Cessation

NCT02697227
Conditions
Cigarette Smoker, Tobacco Use Disorder
Interventions
Behavioral Intervention, Laboratory Biomarker Analysis, Nicotine Patch, Questionnaire Administration, Smoking Cessation Intervention
Behavioral · Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Tobacco Use Disorder
Interventions
NicoDerm CQ patch (GSK Dungarvan), NicoDerm CQ (Alza)
Drug
Lead sponsor
HALEON
Industry
Eligibility
21 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Springfield, Missouri
Completed Not applicable Interventional Accepts healthy volunteers Results available

Attention Deficit Hyperactivity Disorder (ADHD) Smoking Cessation Study

NCT00736255
Conditions
Attention Deficit Hyperactivity Disorder, Nicotine Dependence
Interventions
Transdermal Nicotine Patch, Lis-dexamphetamine (Vyvanse), Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 50 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Healthy
Interventions
Fentanyl
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Cypress, California
Conditions
ADHD
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
13 Years to 17 Years
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
32
States / cities
Scottsdale, Arizona • Lafayette, California • Wildomar, California + 29 more
Conditions
Herpes Labialis
Interventions
Iontophoretic delivery of acyclovir
Drug
Lead sponsor
Transport Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
810 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007
U.S. locations
13
States / cities
Birmingham, Alabama • Santa Rosa, California • Pinellas Park, Florida + 10 more
Conditions
Smoking Cessation, Weight Loss
Interventions
Distress Tolerance, transdermal nicotine patch, Active Health Control
Behavioral · Drug
Lead sponsor
Rhode Island College
Other
Eligibility
18 Years to 64 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Providence, Rhode Island
Active, not recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Remote vs. In-Person Study Evaluation (RISE) Trials: RISE Above Smoking (Trial 1)

NCT06822049
Conditions
Remote vs. In-Person, Remote Visits, In-person Visits
Interventions
Combination Nicotine Replacement Therapy (patch and lozenge)
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 99 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Buffalo, New York • Philadelphia, Pennsylvania
Active, not recruiting Not applicable Interventional

Smoking Cessation Intervention for Cancer Patients

NCT00575718
Conditions
Newly Diagnosed Cancer Patients
Interventions
Hospital Counseling + Nicotine Replacement Therapy. questionaires, Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2026
U.S. locations
1
States / cities
New York, New York
Completed Phase 4 Interventional Accepts healthy volunteers

Midlife Cholesterol Study

NCT00361075
Conditions
Menopause, Postmenopause, Premenopause, Cardiovascular Disease
Interventions
transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)
Drug
Lead sponsor
Northwestern University
Other
Eligibility
47 Years to 55 Years · Female only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2005
U.S. locations
2
States / cities
Chicago, Illinois • Seattle, Washington
Conditions
Osteoarthritis
Interventions
Buprenorphine transdermal patch, Placebo transdermal patch
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
40 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
48
States / cities
Birmingham, Alabama • Haleyville, Alabama • Muscle Shoals, Alabama + 42 more
Conditions
Pain, Postoperative, Ankle Fracture Surgery, Opioid Use Disorder, Opioid Dependence, Opioid Analgesia
Interventions
Buprenorphine Transdermal System, Placebo Patch
Drug
Lead sponsor
Jenna-Leigh Wilson
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

The Menopause Transition: Estrogen Variability, Stress Reactivity and Mood

NCT03003949
Conditions
Perimenopausal Disorder, Stress, Emotional
Interventions
Estradiol Patch, 0.1 Mg/24 Hours Weekly Transdermal Film, Extended Release, Placebo Patch, Progesterone Capsule, Placebo Oral Capsule
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
45 Years to 60 Years · Female only
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
2
States / cities
Chapel Hill, North Carolina
Completed Early Phase 1 Interventional

Inpatient Adolescent Contraception

NCT04423068
Conditions
Pregnancy Related, Contraception, Contraceptive Usage, Contraception Behavior, Pregnancy
Interventions
SexHealth II, Contraceptive
Behavioral · Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
14 Years to 21 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Borderline Personality Disorder
Interventions
Selegiline, Placebo (for Selegiline)
Drug
Lead sponsor
Mood and Anxiety Research, Inc
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
Fresno, California
Conditions
Chronic Low Back Pain
Interventions
Buprenorphine transdermal delivery system
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999
U.S. locations
22
States / cities
Huntsville, Alabama • Phoenix, Arizona • Waterbury, Connecticut + 19 more
Conditions
Smoking Cessation, Depression, Anxiety, Nicotine Dependence, Gender Minority Stress
Interventions
PRIDE QUIT, Enhanced Treatment As Usual (ETAU)
Behavioral
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
Pain, Cancer
Interventions
Fentanyl Transdermal Matrix Patch ZR-02-01
Drug
Lead sponsor
ZARS Pharma Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
2
States / cities
Loma Linda, California • Winston-Salem, North Carolina